NCT04587856 Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
| NCT ID | NCT04587856 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Condition | Myelodysplastic Syndromes |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2021-02-12 |
| Primary Completion | 2025-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 38 participants in total. It began in 2021-02-12 with a primary completion date of 2025-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of MDS according to 2016 WHO criteria * Aged 18y or older * Patients who will receive allogeneic stem cell transplantation (HSCT) * Signed written informed consent according to ICH/EU/GCP and national local laws Exclusion Criteria: * Second HSCT procedure.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04587856 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myelodysplastic Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04587856 currently recruiting?
Yes, NCT04587856 is actively recruiting participants. Contact the research team at p.fazi@gimema.it for enrollment information.
Where is the NCT04587856 trial being conducted?
This trial is being conducted at Bari, Italy, Florence, Italy, Genova, Italy, Perugia, Italy and 3 additional locations.
Who is sponsoring the NCT04587856 clinical trial?
NCT04587856 is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. The trial plans to enroll 38 participants.